^
Association details:
| Biomarker: | High IFNG gene signature |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Published date:
10/16/2023
Excerpt:
Pts with a high baseline IFN-y signature or a PD-L1 expression of ≥1% had a significantly higher 3y EFS rate than pts with low levels (85% vs 61%, p=0.006 and 91% vs 67%, p=0.005, respectively) (Table).
Trial ID:
